Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Apr;17(4):537-44.
doi: 10.1128/CVI.00436-09. Epub 2010 Feb 17.

Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults

Roberto Gasparini  1 , Michele Conversano, Gianni Bona, Giovanni Gabutti, Alessandra Anemona, Peter M Dull, Francesca Ceddia
Affiliations
Randomized Controlled Trial

Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults

Roberto Gasparini et al. Clin Vaccine Immunol. 2010 Apr.

Abstract

This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received either MenACWY-CRM and Tdap, MenACWY-CRM and saline placebo, or Tdap and saline placebo. No significant increase in reactogenicity and no clinically significant vaccine-related adverse events (AEs) occurred when MenACWY-CRM and Tdap were administered concomitantly. Similar immunogenic responses to diphtheria, tetanus, and meningococcal (serogroups A, C, W-135, and Y) antigens were observed, regardless of concomitant vaccine administration. Antipertussis antibody responses were comparable between vaccine groups for filamentous hemagglutinin and were slightly lower, although not clinically significantly, for pertussis toxoid and pertactin when the two vaccines were administered concomitantly. These results indicate that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic and that it can be coadministered with Tdap to adolescents and young adults.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Flowchart of subjects enrolled.
FIG. 2.
FIG. 2.
Proportions of subjects achieving human serum bactericidal assay (hSBA) titers of ≥1:4 against Neisseria meningitidis serogroups A, C, W-135, and Y 1 month after vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) plus a combined tetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap) or with MenACWY-CRM plus saline placebo (SP). Error bars represent 95% confidence intervals.
FIG. 3.
FIG. 3.
Proportions of subjects achieving antibody concentrations of ≥1.0 IU/ml against diphtheria and tetanus antigens 1 month after vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) plus a combined tetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap) or vaccination with Tdap plus saline placebo (SP). Error bars represent 95% confidence intervals.
FIG. 4.
FIG. 4.
Proportion of subjects achieving a 4-fold increase in concentrations of antibodies against pertussis antigens (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) 1 month after vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) plus a combined tetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap) or with Tdap plus saline placebo. The asterisk indicates noninferiority (the lower limit of the 95% confidence interval was ≥−10%). Error bars represent 95% confidence intervals.
FIG. 5.
FIG. 5.
Reverse cumulative distribution of anti-pertussis toxoid (anti-PT) (A), anti-filamentous hemagglutinin (anti-FHA) (B), and anti-pertactin (anti-PRN) (C) titers prevaccination and 1 month postvaccination. MenACWY-CRM, quadrivalent meningococcal conjugate vaccine; Tdap, combined tetanus, reduced diphtheria, and acellular pertussis vaccine.
See this image and copyright information in PMC

References

    1. American Academy of Pediatrics Committee on Infectious Diseases. 2005. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 116:496-505. - PubMed
    1. Bilukha, O. O., N. Rosenstein, et al. 2005. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 54(RR-7):1-21. - PubMed
    1. Broder, K. R., M. M. Cortese, J. K. Iskander, K. Kretsinger, B. A. Slade, K. H. Brown, C. M. Mijalski, T. Tiwari, E. J. Weston, A. C. Chon, P. U. Srivastava, J. S. Moran, B. Schwartz, and T. V. Murphy. 2006. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 55(RR-3):1-34. - PubMed
    1. Burrage, M., A. Robinson, R. Borrow, N. Andrews, J. Southern, J. Findlow, S. Martin, C. Thorton, D. Goldblatt, M. Corbel, D. Sesardic, K. Cartwight, P. Richmond, and E. Miller. 2002. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect. Immun. 70:4946-4954. - PMC - PubMed
    1. Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906. - PubMed

Publication types

MeSH terms